Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
0.1944
-0.0357 (-15.51%)
At close: Nov 18, 2026, 4:00 PM EST
0.1944
0.00 (0.00%)
Pre-market: Nov 19, 2026, 7:20 AM EST
Acumen Pharmaceuticals Employees
As of December 31, 2025, Acumen Pharmaceuticals had 61 total employees, including 60 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes Acumen Pharmaceuticals the 34,062nd largest employer in the world and 4,490th in the United States.
Employees
61
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,704,295
Market Cap
14.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 0 | - | 60 | 1 |
| Dec 31, 2024 | 61 | 9 | 17.31% | 61 | 0 |
| Dec 31, 2023 | 52 | 12 | 30.00% | 51 | 1 |
| Dec 31, 2022 | 40 | 23 | 135.29% | 39 | 1 |
| Dec 31, 2021 | 17 | 10 | 142.86% | 14 | 3 |
| Mar 31, 2021 | 7 | - | - | 7 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| Seres Therapeutics | 66 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Bolt Biotherapeutics | 23 |
| Quantum BioPharma | 17 |
| Tvardi Therapeutics | 12 |
| Actuate Therapeutics | 12 |
ABOS News
- 17 days ago - ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital - TheFly
- 17 days ago - Acumen downgraded to Neutral from Buy at Lucid Capital - TheFly
- 17 days ago - Acumen price target lowered to $1 from $8 at BTIG - TheFly
- 17 days ago - Acumen downgraded to Underperform from Buy at BofA - TheFly
- 19 days ago - Acumen downgraded to Underweight from Overweight at Cantor Fitzgerald - TheFly
- 19 days ago - Acumen downgraded to Neutral from Buy at Citi - TheFly
- 19 days ago - Acumen downgraded to Hold from Buy at Stifel - TheFly
- 20 days ago - Acumen reports ALTITUDE-AD clinical trial did not meet primary endpoint - TheFly